About us Pricing ContactSubscribe

L

Lecia V. Sequist

Harvard UniversityORCID https://orcid.org/0000-0002-8965-6991

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Science Translational Medicine20113,534 citationsFirst authorCorresponding

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

Journal of Clinical Oncology20133,181 citationsFirst authorCorresponding

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

The Lancet Oncology20151,573 citations

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

The Lancet Oncology20161,385 citations

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

Science Translational Medicine20121,320 citations

<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Clinical Cancer Research20161,214 citations

Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells

Science Translational Medicine20131,071 citations

Lecia V. Sequist · Scinovex